Entry

D11360                      Drug

Name

Tirzepatide (JAN/USAN);
Mounjaro (TN)

Product

MOUNJARO (Eli Lilly and Company)

Formula

C225H348N48O68

Exact mass

4810.5249

Mol weight

4813.4514

Sequence

YXEGTFTSDY SIXLDKIAQK AFVQWLIAGG PSSGAPPPS

Type

Peptide

Class

Antidiabetic agent
DG02044 Hypoglycemic agent
DG01493 GLP-1 receptor agonist

Remark

Product:

D11360<US>

Efficacy

Antidiabetic, Gastric inhibitory polypeptide receptor agonist, Glucagon-like peptide 1 (GLP-1) receptor agonist

Disease

Type 2 diabetes mellitus [DS:H00409]

Comment

Treatment of type 2 diabetes

Target

GIPR [HSA:2696] [KO:K04580]
GLP1R [HSA:2740] [KO:K04581]

Pathway

hsa04024

cAMP signaling pathway

hsa04080

Neuroactive ligand-receptor interaction

hsa04911

Insulin secretion

Interaction

Brite

Drug groups [BR:br08330]
Antidiabetic agent
  DG02044  Hypoglycemic agent
   DG01493  GLP-1 receptor agonist
    D11360  Tirzepatide
Drug classes [BR:br08332]
Antidiabetic agent
  DG01493  GLP-1 receptor agonist
   D11360  Tirzepatide
  DG02044  Hypoglycemic agent
   D11360  Tirzepatide
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
  Secretin receptor family
   Glucagon
    GLP1R
     D11360  Tirzepatide (JAN/USAN) <US>
   Gastric inhibitory polypeptide
    GIPR
     D11360  Tirzepatide (JAN/USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D11360
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D11360

Other DBs

CAS:	2023788-19-2

PubChem:

384585338